Acadia Healthcare Company, Inc. $ACHC Shares Purchased by Prosight Management LP

Prosight Management LP grew its position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 18.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 250,000 shares of the company’s stock after purchasing an additional 38,184 shares during the period. Acadia Healthcare makes up approximately 1.4% of Prosight Management LP’s holdings, making the stock its 24th biggest position. Prosight Management LP owned 0.27% of Acadia Healthcare worth $6,190,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ACHC. Abrams Bison Investments LLC boosted its position in shares of Acadia Healthcare by 96.7% during the second quarter. Abrams Bison Investments LLC now owns 3,580,000 shares of the company’s stock worth $81,230,000 after buying an additional 1,760,000 shares during the period. Wellington Management Group LLP increased its position in Acadia Healthcare by 11.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,423,548 shares of the company’s stock valued at $233,327,000 after acquiring an additional 993,205 shares during the period. Amundi raised its stake in Acadia Healthcare by 1,006,804.5% during the 2nd quarter. Amundi now owns 896,145 shares of the company’s stock valued at $20,782,000 after acquiring an additional 896,056 shares in the last quarter. Vanguard Group Inc. raised its stake in Acadia Healthcare by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 9,417,045 shares of the company’s stock valued at $233,166,000 after acquiring an additional 681,278 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in Acadia Healthcare during the 2nd quarter worth $11,401,000.

Acadia Healthcare Price Performance

NASDAQ ACHC opened at $23.52 on Friday. Acadia Healthcare Company, Inc. has a 1 year low of $11.43 and a 1 year high of $31.04. The business’s fifty day moving average is $16.80 and its two-hundred day moving average is $18.78. The stock has a market capitalization of $2.17 billion, a P/E ratio of -1.93, a P/E/G ratio of 8.16 and a beta of 0.74. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55.

Acadia Healthcare (NASDAQ:ACHC) last issued its earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Acadia Healthcare had a positive return on equity of 6.53% and a negative net margin of 33.29%.The business had revenue of $821.46 million for the quarter, compared to analysts’ expectations of $800.10 million. During the same period in the previous year, the firm posted $0.64 EPS. The company’s quarterly revenue was up 6.1% on a year-over-year basis. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. On average, research analysts forecast that Acadia Healthcare Company, Inc. will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on ACHC. Weiss Ratings reissued a “sell (d)” rating on shares of Acadia Healthcare in a report on Wednesday, January 21st. Barclays upped their price objective on shares of Acadia Healthcare from $14.00 to $20.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. UBS Group raised their target price on shares of Acadia Healthcare from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Leerink Partners boosted their price target on shares of Acadia Healthcare from $14.00 to $22.00 and gave the stock a “market perform” rating in a research report on Thursday, February 26th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Acadia Healthcare in a research note on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $21.15.

Key Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia added Daniel Cancelmi to its Board of Directors, a governance move that can be viewed positively as expanding board expertise and oversight. Article Title
• Neutral Sentiment: Reported short-interest data shows zero shares and days-to-cover of 0.0 — the release appears to contain anomalous or missing data (NaN/0) and therefore provides no clear signal about bearish positioning.
• Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and keeps a “Hold” rating. Key changes include Q2 2026 EPS cut to $0.49 (from $0.66), FY2026 to $1.48 (from $1.85), and FY2027 to $1.55 (from $1.96), plus several quarter-by-quarter reductions across 2026–2027. These downward revisions lower investor expectations and are the main reason for today’s downward pressure on the stock.

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.